Options
柚皮素透過下調 Akt 活性抑制人類膀胱癌細胞的生長及遷移
Date Issued
2012
Author(s)
黃逸群
Yi-Chiun
Advisor
許立松
Abstract
根據美國2012年癌症協會統計(American cancer society 2012 statistics)2012年男性膀胱癌病發案件共計55600件,且所有男性因膀胱癌導致死亡排名第六名至今上述統計仍然不斷上升之中,其中膀胱癌在男女性病發率為3比1,其誘導膀胱癌病因包括許多環境致癌因子所導致,過去研究指出和抽菸有極大的關聯性;然而為了治療膀胱癌病人脫離病痛過去使用一些化療藥物、放射性治療或進行人工手術切除皆會增加各種療程中所帶來的併發症或腫瘤轉移等各項風險。因此發展新穎的天然抗癌藥物來作為癌症的預防或是治癒方針是目前研究抗癌中重要的課題。柚皮素(naringenin)為一種類黃酮化合物家族成員之一,可廣泛的發現它存在許多水果當中,過去柚皮素被報導具有抗發炎、抗氧化、清除自由基及降血脂等多項療效,但目前柚皮素在治療膀胱機制方面並未有文獻期刊報導過,因此由我們的實驗結果中證實柚皮素的確可以抑制膀胱癌的生長、遷移及細胞週期等效用。在短時間24小時不同濃度柚皮素處理下,膀胱癌細胞中除了ERK和p38蛋白表現不變,其他包括細胞存活率、MMP-2、uPA、磷酸化Akt與細胞核NFκB之表現量與活性,皆可分別藉由MTT assay 、Zymography assay以及western blotting 觀察結果隨著藥物濃度上升而隨之下降趨勢,另外在長時間48小時不同濃度柚皮素處理下,ERK蛋白表現量卻意外性的具有活化之趨勢,也是日後我們必須再進一步研究討論的問題。更進一步的藉由流式細胞儀分析下,在48小時不同濃度的柚皮素作用會導致膀胱癌細胞週期停止在S phase,整合上述實驗結果我們發現膀胱癌的細胞存活率、遷移力下降及細胞週期的停滯仰賴於柚皮素具有下調Akt磷酸化之效用而影響了下游訊號路徑的傳遞間接地抑制膀胱癌。在此我們相信使用天然柚皮素治癒膀胱癌具有良好的療效,也信任柚皮素做為抗癌藥物或抗腫瘤侵襲藥物的發展上深
The incidence of bladder cancer is continuing increase, with an estimated 55,600 new cases in the United States in 2012. The male-to-female ratio is 3:1. A number of aetiological factors are associated with the development of bladder cancer. In the previous study evidenced that cigarette smoking is the main carcinogen. In order to cure the patient who is suffered by the bladder cancer. Treatment with cytostatic drug is related with increased risk of bladder cancer, as is treatment with radical cystectomy or radiotherapy. Therefore, development of novel nature drug or drug therapy was important issue. Naringenin (NAR), a kind of flavonoids, which is plentiful in citrus fruits, has been shown to exhibit anti-flammatory, anti-oxidant and hypolipidemic effects. However, the properties of naringenin in human bladder cancer have not been clarified. In this study, we demonstrated that NAR inhibited proliferation, migration and cell cycle prograssion of TSGH-8301 human bladder cell. Treatment with naringenin caused reducing of cell proliferation by MTT assay in a dose-dependent manner. Zymography assay revealed that NAR decreased matrix metalloproteinase (MMP-2) and urokinase - type plasminogen activator (u-PA) activities. As we expected, it also inhibited migration as evidenced by wound healing assay. Western blot analysis indicated that NAR reduced the phosphorylation level of AKT and the nuclear protein expression of NFκB but not ERK or p38 protein at 24 h treatment. Interestingly, it inducted phosphorylation level of ERK at 48 h treatment. Thus, it remains to be resolved. Furthermore, we found that NAR were caused S phase arrest of cell cycle by flow cytometry. These observations indicate that NAR exerts anti-cancer by the down-regulation of pAKT, inhibited proliferation, motility and cell cycle arrest in human bladder cancer cell. Hence, our findings suggested that NAR might be available for another strategy of treatment of human bladder cancer.
Type
thesis
File(s)
No Thumbnail Available
Name
100CSMU5107017-001.zip
Size
2.3 MB
Format
Unknown
Checksum
(MD5):0f3bd59505f3e77442d1d38761be9191